Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

CONCLUSION: Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.PMID:37067546 | DOI:10.1007/s00432-023-04766-3

Source: Cancer Control - April 17, 2023 Category: Cancer & Oncology Authors: Ahmet Bilici Sinan Koca Mustafa Karaagac Sabin Goktas Aydin Emrah Eraslan Muhammed Ali Kaplan Birol Ocak Sema Sezgin Goksu Semra Paydas Fahri Akgul Sumeyye Derin Yakup Ergun Emre Yekeduz Cihan Erol Deniz Tataroglu Ozyukseler Atike Gokcen Demiray Mustafa K Source Type: research